336 related articles for article (PubMed ID: 26392761)
1. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Huisman EL; Cockle SM; Ismaila AS; Karabis A; Punekar YS
Int J Chron Obstruct Pulmon Dis; 2015; 10():1863-81. PubMed ID: 26392761
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
3. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
[TBL] [Abstract][Full Text] [Related]
9. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
10. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Cope S; Donohue JF; Jansen JP; Kraemer M; Capkun-Niggli G; Baldwin M; Buckley F; Ellis A; Jones P
Respir Res; 2013 Oct; 14(1):100. PubMed ID: 24093477
[TBL] [Abstract][Full Text] [Related]
14. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Ismaila AS; Huisman EL; Punekar YS; Karabis A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
[TBL] [Abstract][Full Text] [Related]
17. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
20. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
